Humana Inc
Change company Symbol lookup
Select an option...
HUM Humana Inc
UAL United Airlines Holdings Inc
TEL TE Connectivity Ltd
HPGN HypGen Inc
IX Orix Corp
WHR Whirlpool Corp
PG Procter & Gamble Co
PWJAX PGIM Jennison International Opportunities Fund- Class A
MBWM Mercantile Bank Corp
MEIUF Meitu Inc
Go

Health Care : Health Care Providers & Services | Large Cap Blend
Company profile

Humana Inc. is a health and well-being company. The Company's segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, including dental, vision, and other supplemental health and financial protection products. The Healthcare Services segment includes services offered to its health plan members, as well as to third parties, including pharmacy solutions, provider services, home-based services and clinical programs, as well as services and capabilities to manage population health. The Individual Commercial segment includes Individual Commercial products marketed under the HumanaOne brand.

Premarket

Last Trade
Delayed
$443.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$443.00
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
77

10-day average volume:
923,916
77

Tesla stock upgraded by Wedbush after 'paradigm changer' delivery numbers

10:01 pm ET April 4, 2021 (MarketWatch)
Print

By Mike Murphy

Wedbush's Ives boosts outlook, sees Tesla's profitability improving in the coming years

Wedbush Securities has upgraded its outlook for Tesla Inc., following stronger-than-expected quarterly deliveries.

On Sunday, Wedbush raised its price target for Tesla (TSLA), to $1,000 a share from $950, with a long-term bull-case price of $1,300 a share. Tesla shares closed Thursday at $661.75 (markets were closed Friday).

Wedbush analyst Daniel Ives also changed his rating from hold to outperform. "In our opinion the 1Q delivery numbers released on Friday was a paradigm changer," he said in a note.

On Friday, Tesla reported first-quarter deliveries, (https://www.marketwatch.com/story/tesla-delivered-184800-vehicles-in-q1-blowing-past-estimates-2021-04-02) its proxy for sales, totaling 184,800 vehicles, blowing past the FactSet consensus of 168,000. The Silicon Valley electric-vehicle maker said it produced just over 180,000 vehicles in the period in what Ives called a "drop the mic" number (https://www.marketwatch.com/story/strong-tesla-sales-are-a-drop-the-mic-moment-analyst-says-11617378970?mod=home-page).

"We now believe Tesla could exceed 850k deliveries for the year with 900k a stretch goal, despite the chip shortage and various supply chain issues lingering across the auto sector," Ives said Sunday. He added "eye popping delivery numbers coming out of China cannot be ignored with the trajectory on pace to represent 40% of deliveries for Musk & Co. by 2022."

Ives and his team also see Tesla's profitability significantly improving over the next three to four years, with the potential for annual earnings per share of $20 by 2026.

Tesla shares are down 6.2% year to date, but have skyrocketed 628% over the past 12 months.

-Mike Murphy; 415-439-6400; AskNewswires@dowjones.com

	

(END) Dow Jones Newswires

April 04, 2021 22:01 ET (02:01 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.